News
ABBV
223.14
+1.02%
2.25
54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'
Seeking Alpha · 3h ago
1 Reason I'm Never Selling AbbVie Stock
The Motley Fool · 5h ago
AbbVie Sues HHS Over Selection Of Botox For IRA Medicare Drug Negotiations
Benzinga · 17h ago
2 Urgent Sells And 2 No Brainer Dividend Buys
Seeking Alpha · 18h ago
AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
TipRanks · 23h ago
P/E Ratio Insights for AbbVie
Benzinga · 1d ago
Assessing AbbVie (ABBV) Valuation After Strong Q4 Results And New Rinvoq Filings
Simply Wall St · 1d ago
AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
TipRanks · 1d ago
Dividend Kings: No Ideal Buys In February's 57
Seeking Alpha · 2d ago
Gilead Sciences: Buy This Stock For Both Dividend And Growth
Seeking Alpha · 2d ago
Did AbbVie’s (ABBV) Q4 Beat and RINVOQ Vitiligo Filings Just Reframe Its Immunology Story?
Simply Wall St · 2d ago
Weekly Report: what happened at ABBV last week (0202-0206)?
Weekly Report · 3d ago
3 Market-Beating Stocks to Research Further
Barchart · 3d ago
AbbVie Seeks Rinvoq Vitiligo Approval And Extends Immunology Growth Story
Simply Wall St · 4d ago
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week
Seeking Alpha · 4d ago
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Seeking Alpha · 5d ago
Dividend Champion, Contender, And Challenger Highlights: Week Of February 8
Seeking Alpha · 5d ago
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder
Benzinga · 5d ago
AbbVie (ABBV) One Off US$5.0b Loss Tests Bullish High P/E Valuation Narratives
Simply Wall St · 5d ago
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
TipRanks · 6d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).